XNAS 13 Oct, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 11.71 per share. | 23 Jul 2026 | 12,500 | 702,770 | - | 11.7 | 146,425 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 11.58 per share. | 23 Jul 2026 | 12,500 | 715,270 | - | 11.6 | 144,738 | Common Stock |
| Mr. Andrew S. Rappaport | Director | 18 Jun 2026 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | ||
| Ms. Cynthia M. Butitta | Director | 18 Jun 2026 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | ||
| Mr. Ian T. Clark | Director | 18 Jun 2026 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | ||
| Dr. Sandra J. Horning, M.D. | Director | 18 Jun 2026 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | ||
| Dr. Graham Walmsley, M.D.,PhD | Director | 18 Jun 2026 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | ||
| Ms. Yi Larson | Director | 18 Jun 2026 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | ||
| Dr. Gorjan Hrustanovic, PhD | Director | 18 Jun 2026 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | ||
| Dr. Cyrus L. Harmon, PhD | Director | 18 Jun 2026 | 29,500 | 29,500 | - | - | Stock Option (Right to Buy) | ||
| Dr. Prakash Raman, PhD | Director | 18 Jun 2026 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | ||
| Dr. Prakash Raman, PhD | Director | 28 Apr 2026 | 24,150 | 24,150 | - | - | Stock Option (Right to Buy) | ||
| Dr. Prakash Raman, PhD | Director | 28 Apr 2026 | 2,911 | 2,911 | - | - | Stock Option (Right to Buy) | ||
| Ms. Shawnte M. Mitchell, J.D. | CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.37 per share. | 03 Mar 2026 | 15,000 | 15,000 | - | 4.4 | 65,550 | Common Stock |
| Ms. Shawnte M. Mitchell, J.D. | CHIEF LEGAL OFFICER | 03 Mar 2026 | 25,000 | 410,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Shawnte M. Mitchell, J.D. | CHIEF LEGAL OFFICER | 03 Mar 2026 | 15,000 | 435,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Shawnte M. Mitchell, J.D. | CHIEF LEGAL OFFICER | Sale of securities on an exchange or to another person at price $ 24.69 per share. | 03 Mar 2026 | 233 | 0 | - | 24.7 | 5,753 | Comon Stock |
| Ms. Shawnte M. Mitchell, J.D. | CHIEF LEGAL OFFICER | Sale of securities on an exchange or to another person at price $ 24.25 per share. | 03 Mar 2026 | 24,767 | 233 | - | 24.3 | 600,600 | Common Stock |
| Ms. Shawnte M. Mitchell, J.D. | CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.37 per share. | 03 Mar 2026 | 25,000 | 25,000 | - | 4.4 | 109,250 | Common Stock |
| Ms. Shawnte M. Mitchell, J.D. | CHIEF LEGAL OFFICER | Sale of securities on an exchange or to another person at price $ 23.01 per share. | 03 Mar 2026 | 15,000 | 0 | - | 23.0 | 345,150 | Common Stock |
| Dr. Sean P. Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | 02 Feb 2026 | 275,000 | 275,000 | - | - | Performance Stock Options (Right to Buy) | ||
| Dr. Sean P. Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | 02 Feb 2026 | 850,000 | 850,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Shawnte M. Mitchell, J.D. | CHIEF LEGAL OFFICER | 02 Feb 2026 | 56,250 | 56,250 | - | - | Performance Stock Options (Right to Buy) | ||
| Ms. Shawnte M. Mitchell, J.D. | CHIEF LEGAL OFFICER | 02 Feb 2026 | 220,000 | 220,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | 02 Feb 2026 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | 02 Feb 2026 | 106,250 | 106,250 | - | - | Performance Stock Options (Right to Buy) | ||
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | 02 Feb 2026 | 106,250 | 106,250 | - | - | Performance Stock Options (Right to Buy) | ||
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | 02 Feb 2026 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Sasha Lu Austin | VP of Finance and Controller | 02 Feb 2026 | 29,250 | 29,250 | - | - | Stock Option (Right to Buy) | ||
| Ms. Sasha Lu Austin | VP of Finance and Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 11,700 | 16,188 | - | 0 | Common Stock | |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 26.88 per share. | 20 Jan 2026 | 10,000 | 727,770 | - | 26.9 | 268,800 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 26.88 per share. | 20 Jan 2026 | 10,000 | 727,770 | - | 26.9 | 268,800 | - |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 29.12 per share. | 14 Jan 2026 | 3,489 | 737,770 | - | 29.1 | 101,600 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 29.12 per share. | 14 Jan 2026 | 3,489 | 737,770 | - | 29.1 | 101,600 | - |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Sale of securities on an exchange or to another person at price $ 28.01 per share. | 13 Jan 2026 | 3,822 | 239,727 | - | 28.0 | 107,054 | Common Stock |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Sale of securities on an exchange or to another person at price $ 28.73 per share. | 13 Jan 2026 | 100,000 | 139,727 | - | 28.7 | 2,873,000 | Common Stock |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Sale of securities on an exchange or to another person at price $ 28.01 per share. | 13 Jan 2026 | 3,822 | 239,727 | - | 28.0 | 107,054 | - |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Sale of securities on an exchange or to another person at price $ 28.73 per share. | 13 Jan 2026 | 100,000 | 139,727 | - | 28.7 | 2,873,000 | - |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 28.34 per share. | 12 Jan 2026 | 10,000 | 144,846 | - | 28.3 | 283,400 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.87 per share. | 12 Jan 2026 | 50,000 | 592,761 | - | 4.9 | 243,500 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 27.60 per share. | 12 Jan 2026 | 49,800 | 542,961 | - | 27.6 | 1,374,480 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 28.49 per share. | 12 Jan 2026 | 200 | 542,761 | - | 28.5 | 5,698 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.87 per share. | 12 Jan 2026 | 50,000 | 592,761 | - | 4.9 | 243,500 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 28.60 per share. | 12 Jan 2026 | 14,997 | 577,764 | - | 28.6 | 428,914 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 28.99 per share. | 12 Jan 2026 | 35,003 | 542,761 | - | 29.0 | 1,014,737 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | 12 Jan 2026 | 50,000 | 100,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | 12 Jan 2026 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 28.34 per share. | 12 Jan 2026 | 10,000 | 144,846 | - | 28.3 | 283,400 | - |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.87 per share. | 12 Jan 2026 | 50,000 | 592,761 | - | 4.9 | 243,500 | - |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 27.60 per share. | 12 Jan 2026 | 49,800 | 542,961 | - | 27.6 | 1,374,480 | - |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 28.49 per share. | 12 Jan 2026 | 200 | 542,761 | - | 28.5 | 5,698 | - |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.87 per share. | 12 Jan 2026 | 50,000 | 592,761 | - | 4.9 | 243,500 | - |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 28.60 per share. | 12 Jan 2026 | 14,997 | 577,764 | - | 28.6 | 428,914 | - |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 28.99 per share. | 12 Jan 2026 | 35,003 | 542,761 | - | 29.0 | 1,014,737 | - |
| Dr. Sean P. Bohen, M.D.,PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Dec 2025 | 8,500 | 237,650 | - | 0 | Common Stock | |
| Dr. Sean Bohen, M.D.,PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Dec 2025 | 8,500 | 237,650 | - | 0 | - | |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 28.53 per share. | 22 Dec 2025 | 2,881 | 741,259 | - | 28.5 | 82,195 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 28.53 per share. | 22 Dec 2025 | 2,881 | 741,259 | - | 28.5 | 82,195 | - |
| Mr. Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.41 per share. | 19 Dec 2025 | 209,690 | 209,690 | - | 4.4 | 923,894 | Common Stock |
| Mr. Ian T. Clark | Director | 19 Dec 2025 | 12,070 | 12,080 | - | - | Stock Option (Right to Buy) | ||
| Mr. Ian T. Clark | Director | 19 Dec 2025 | 21,520 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Ian T. Clark | Director | 19 Dec 2025 | 21,520 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Ian T. Clark | Director | 19 Dec 2025 | 209,690 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 30.48 per share. | 19 Dec 2025 | 41,840 | 0 | - | 30.5 | 1,275,283 | Common Stock |
| Mr. Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 29.71 per share. | 19 Dec 2025 | 193,056 | 41,840 | - | 29.7 | 5,735,694 | Common Stock |
| Mr. Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 28.83 per share. | 19 Dec 2025 | 29,904 | 234,896 | - | 28.8 | 862,132 | Common Stock |
| Mr. Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.08 per share. | 19 Dec 2025 | 12,070 | 264,800 | - | 4.1 | 49,246 | Common Stock |
| Mr. Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 19 Dec 2025 | 21,520 | 252,730 | - | 7.8 | 168,717 | Common Stock |
| Mr. Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.61 per share. | 19 Dec 2025 | 21,520 | 231,210 | - | 3.6 | 77,687 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 30.40 per share. | 19 Dec 2025 | 43,729 | 557,927 | - | 30.4 | 1,329,362 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2025 | 9,000 | 542,881 | - | 0 | Common Stock | |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 31.39 per share. | 19 Dec 2025 | 6,046 | 551,881 | - | 31.4 | 189,784 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 28.08 per share. | 19 Dec 2025 | 1,225 | 601,656 | - | 28.1 | 34,398 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | 19 Dec 2025 | 50,000 | 156,818 | - | - | Stock Option (Right to Buy) | ||
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.25 per share. | 19 Dec 2025 | 40,000 | 173,997 | - | 15.3 | 610,000 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.03 per share. | 19 Dec 2025 | 57,079 | 116,918 | - | 28.0 | 1,599,924 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.93 per share. | 19 Dec 2025 | 12,921 | 103,997 | - | 28.9 | 373,805 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.25 per share. | 19 Dec 2025 | 42,818 | 146,815 | - | 15.3 | 652,975 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.02 per share. | 19 Dec 2025 | 7,182 | 153,997 | - | 7.0 | 50,418 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.04 per share. | 19 Dec 2025 | 100,000 | 53,997 | - | 28.0 | 2,804,000 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.02 per share. | 19 Dec 2025 | 50,000 | 103,997 | - | 7.0 | 351,000 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.66 per share. | 19 Dec 2025 | 99,509 | 4,488 | - | 27.7 | 2,752,419 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | 19 Dec 2025 | 40,000 | 155,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | 19 Dec 2025 | 42,818 | 112,182 | - | - | Stock Option (Right to Buy) | ||
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | 19 Dec 2025 | 7,182 | 206,818 | - | - | Stock Option (Right to Buy) | ||
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 28.08 per share. | 19 Dec 2025 | 1,225 | 601,656 | - | 28.1 | 34,398 | - |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 30.40 per share. | 19 Dec 2025 | 43,729 | 557,927 | - | 30.4 | 1,329,362 | - |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 31.39 per share. | 19 Dec 2025 | 6,046 | 551,881 | - | 31.4 | 189,784 | - |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2025 | 9,000 | 542,881 | - | 0 | - | |
| Mr. Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.41 per share. | 19 Dec 2025 | 209,690 | 209,690 | - | 4.4 | 923,894 | - |
| Mr. Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.61 per share. | 19 Dec 2025 | 21,520 | 231,210 | - | 3.6 | 77,687 | - |
| Mr. Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 19 Dec 2025 | 21,520 | 252,730 | - | 7.8 | 168,717 | - |
| Mr. Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.08 per share. | 19 Dec 2025 | 12,070 | 264,800 | - | 4.1 | 49,246 | - |
| Mr. Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 28.83 per share. | 19 Dec 2025 | 29,904 | 234,896 | - | 28.8 | 862,132 | - |
| Mr. Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 29.71 per share. | 19 Dec 2025 | 193,056 | 41,840 | - | 29.7 | 5,735,694 | - |
| Mr. Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 30.48 per share. | 19 Dec 2025 | 41,840 | 0 | - | 30.5 | 1,275,283 | - |
| Dr. Naseem Zojwalla | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.25 per share. | 19 Dec 2025 | 40,000 | 173,997 | - | 15.3 | 610,000 | - |
| Dr. Naseem Zojwalla | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.03 per share. | 19 Dec 2025 | 57,079 | 116,918 | - | 28.0 | 1,599,924 | - |
| Dr. Naseem Zojwalla | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.93 per share. | 19 Dec 2025 | 12,921 | 103,997 | - | 28.9 | 373,805 | - |
| Dr. Naseem Zojwalla | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.25 per share. | 19 Dec 2025 | 42,818 | 146,815 | - | 15.3 | 652,975 | - |
| Dr. Naseem Zojwalla | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.02 per share. | 19 Dec 2025 | 7,182 | 153,997 | - | 7.0 | 50,418 | - |
| Dr. Naseem Zojwalla | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.04 per share. | 19 Dec 2025 | 100,000 | 53,997 | - | 28.0 | 2,804,000 | - |
| Dr. Naseem Zojwalla | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.02 per share. | 19 Dec 2025 | 50,000 | 103,997 | - | 7.0 | 351,000 | - |
| Dr. Naseem Zojwalla | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.66 per share. | 19 Dec 2025 | 99,509 | 4,488 | - | 27.7 | 2,752,419 | - |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Dec 2025 | 75,000 | 243,549 | - | 0 | Common Stock | |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Dec 2025 | 75,000 | 243,549 | - | 0 | - | |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Nov 2025 | 225,000 | 318,549 | - | 0 | Common Stock | |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Nov 2025 | 225,000 | 318,549 | - | 0 | - | |
| Mr. Andrew S. Rappaport | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 21 Nov 2025 | 35,868 | 35,868 | - | 0.4 | 13,989 | Common Stock |
| Mr. Andrew S. Rappaport | Director | 21 Nov 2025 | 35,868 | 0 | - | - | Stock Option (right to buy) | ||
| Mr. Andrew S. Rappaport | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 21 Nov 2025 | 35,868 | 0 | - | 0 | Common Stock | |
| Mr. Andrew S. Rappaport | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 21 Nov 2025 | 35,868 | 35,868 | - | 0.4 | 13,989 | - |
| Mr. Andrew S. Rappaport | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 21 Nov 2025 | 35,868 | 0 | - | 0 | - | |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 8.04 per share. | 16 Sep 2025 | 10,000 | 754,140 | - | 8.0 | 80,400 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 8.32 per share. | 16 Sep 2025 | 3,086 | 117,028 | - | 8.3 | 25,676 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 8.08 per share. | 16 Sep 2025 | 1,914 | 120,114 | - | 8.1 | 15,465 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 8.33 per share. | 16 Sep 2025 | 10,000 | 744,140 | - | 8.3 | 83,300 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 8.04 per share. | 16 Sep 2025 | 10,000 | 754,140 | - | 8.0 | 80,400 | - |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 8.33 per share. | 16 Sep 2025 | 10,000 | 744,140 | - | 8.3 | 83,300 | - |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 8.08 per share. | 16 Sep 2025 | 1,914 | 120,114 | - | 8.1 | 15,465 | - |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 8.32 per share. | 16 Sep 2025 | 3,086 | 117,028 | - | 8.3 | 25,676 | - |
| Mr. Andrew S. Rappaport | Director | 11 Jun 2025 | 24,150 | 24,150 | - | - | Stock Option (right to buy) | ||
| Ms. Cynthia M. Butitta | Director | 11 Jun 2025 | 24,150 | 24,150 | - | - | Stock Option (right to buy) | ||
| Mr. Ian T. Clark | Director | 11 Jun 2025 | 24,150 | 24,150 | - | - | Stock Option (right to buy) | ||
| Dr. Sandra J. Horning, M.D. | Director | 11 Jun 2025 | 24,150 | 24,150 | - | - | Stock Option (right to buy) | ||
| Dr. Graham Walmsley, M.D.,PhD | Director | 11 Jun 2025 | 24,150 | 24,150 | - | - | Stock Option (right to buy) | ||
| Ms. Yi Larson | Director | 11 Jun 2025 | 24,150 | 24,150 | - | - | Stock Option (right to buy) | ||
| Dr. Gorjan Hrustanovic, PhD | Director | 11 Jun 2025 | 24,150 | 24,150 | - | - | Stock Option (right to buy) | ||
| Dr. Cyrus L. Harmon, PhD | Director | 11 Jun 2025 | 24,150 | 24,150 | - | - | Stock Option (right to buy) | ||
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | 28 Feb 2025 | 320,000 | 320,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean P. Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | 28 Feb 2025 | 650,000 | 650,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | 28 Feb 2025 | 205,000 | 205,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | 28 Feb 2025 | 205,000 | 205,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Shawnte M. Mitchell, J.D. | CHIEF LEGAL OFFICER | 28 Feb 2025 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | 16 Dec 2024 | 14,000 | 112,840 | - | - | Stock Option (Right to Buy) | ||
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.87 per share. | 16 Dec 2024 | 14,000 | 129,509 | - | 4.9 | 68,180 | Common Stock |
| Dr. Graham Walmsley, M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 6.75 per share. | 13 Dec 2024 | 700,761 | 0 | - | 6.8 | 4,730,137 | Common Stock |
| Dr. Graham Walmsley, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 6.75 per share. | 13 Dec 2024 | 700,761 | 1,408,875 | - | 6.8 | 4,730,137 | Common Stock |
| Dr. Graham Walmsley, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 6.75 per share. | 13 Dec 2024 | 700,761 | 700,761 | - | 6.8 | 4,730,137 | Common Stock |
| Dr. Graham Walmsley, M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 6.75 per share. | 13 Dec 2024 | 700,761 | 0 | - | 6.8 | 4,730,137 | Common Stock |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 68,250 | 578,708 | - | 0 | Common Stock | |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Sale of securities on an exchange or to another person at price $ 9.39 per share. | 09 Dec 2024 | 406 | 543,549 | - | 9.4 | 3,812 | Common Stock |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Sale of securities on an exchange or to another person at price $ 8.66 per share. | 09 Dec 2024 | 17,950 | 543,955 | - | 8.7 | 155,447 | Common Stock |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Sale of securities on an exchange or to another person at price $ 9.37 per share. | 09 Dec 2024 | 16,803 | 561,905 | - | 9.4 | 157,444 | Common Stock |
| Dr. Sean P. Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 204,750 | 351,164 | - | 0 | Common Stock | |
| Dr. Sean P. Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 9.39 per share. | 09 Dec 2024 | 1,267 | 241,662 | - | 9.4 | 11,897 | Common Stock |
| Dr. Sean P. Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 8.66 per share. | 09 Dec 2024 | 55,907 | 242,929 | - | 8.7 | 484,155 | Common Stock |
| Dr. Sean P. Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 9.37 per share. | 09 Dec 2024 | 52,328 | 298,836 | - | 9.4 | 490,313 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 9.37 per share. | 09 Dec 2024 | 8,256 | 772,277 | - | 9.4 | 77,359 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 29,250 | 780,533 | - | 0 | Common Stock | |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 9.39 per share. | 09 Dec 2024 | 179 | 764,140 | - | 9.4 | 1,681 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 8.66 per share. | 09 Dec 2024 | 7,958 | 764,319 | - | 8.7 | 68,916 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 8.66 per share. | 09 Dec 2024 | 13,314 | 598,633 | - | 8.7 | 115,299 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 9.38 per share. | 09 Dec 2024 | 12,452 | 611,947 | - | 9.4 | 116,800 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 48,750 | 624,399 | - | 0 | Common Stock | |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 9.39 per share. | 09 Dec 2024 | 300 | 598,333 | - | 9.4 | 2,817 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 9.37 per share. | 09 Dec 2024 | 13,283 | 130,031 | - | 9.4 | 124,462 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 9.39 per share. | 09 Dec 2024 | 320 | 115,509 | - | 9.4 | 3,005 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.66 per share. | 09 Dec 2024 | 14,202 | 115,829 | - | 8.7 | 122,989 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 52,000 | 143,314 | - | 0 | Common Stock | |
| Mr. Shane Kovacs | Ch. Operating & Financial Off. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.02 per share. | 15 Nov 2024 | 25,000 | 510,458 | - | 7.0 | 175,500 | Common Stock |
| Mr. Shane Kovacs | Ch. Operating & Financial Off. | 15 Nov 2024 | 25,000 | 162,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 15.55 per share. | 29 Jul 2024 | 934 | 751,283 | - | 15.6 | 14,524 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 15.58 per share. | 29 Jul 2024 | 4,066 | 752,217 | - | 15.6 | 63,348 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 12.26 per share. | 11 Jul 2024 | 5,000 | 756,283 | - | 12.3 | 61,300 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 10.77 per share. | 28 Jun 2024 | 20,000 | 761,283 | - | 10.8 | 215,400 | Common Stock |
| Mr. Andrew S. Rappaport | Director | 14 Jun 2024 | 23,000 | 23,000 | - | - | Stock Option (right to buy) | ||
| Ms. Cynthia M. Butitta | Director | 14 Jun 2024 | 23,000 | 23,000 | - | - | Stock Option (right to buy) | ||
| Mr. Ian T. Clark | Director | 14 Jun 2024 | 23,000 | 23,000 | - | - | Stock Option (right to buy) | ||
| Dr. Sandra J. Horning, M.D. | Director | 14 Jun 2024 | 23,000 | 23,000 | - | - | Stock Option (right to buy) | ||
| Dr. Graham Walmsley, M.D.,PhD | Director | 14 Jun 2024 | 23,000 | 23,000 | - | - | Stock Option (right to buy) | ||
| Ms. Yi Larson | Director | 14 Jun 2024 | 23,000 | 23,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Gorjan Hrustanovic, PhD | Director | 14 Jun 2024 | 23,000 | 23,000 | - | - | Stock Option (right to buy) | ||
| Dr. Cyrus L. Harmon, PhD | Director | 14 Jun 2024 | 23,000 | 23,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Graham Walmsley, M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 14.85 per share. | 04 Jun 2024 | 475,000 | 708,114 | - | 14.9 | 7,053,750 | Common Stock |
| Dr. Graham Walmsley, M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 14.85 per share. | 04 Jun 2024 | 700,000 | 700,761 | - | 14.9 | 10,395,000 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 12.33 per share. | 31 May 2024 | 5,000 | 781,283 | - | 12.3 | 61,650 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 10.93 per share. | 31 May 2024 | 5,000 | 786,283 | - | 10.9 | 54,650 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 9.41 per share. | 31 May 2024 | 15,000 | 791,283 | - | 9.4 | 141,150 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.87 per share. | 24 May 2024 | 9,460 | 89,824 | - | 4.9 | 46,070 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | 24 May 2024 | 9,460 | 126,840 | - | - | Stock Option (Right to Buy) | ||
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 10.92 per share. | 06 May 2024 | 5,000 | 806,283 | - | 10.9 | 54,600 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 9.51 per share. | 30 Apr 2024 | 15,000 | 811,283 | - | 9.5 | 142,650 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 10.97 per share. | 28 Mar 2024 | 20,000 | 826,283 | - | 11.0 | 219,400 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.87 per share. | 18 Mar 2024 | 13,700 | 80,364 | - | 4.9 | 66,719 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | 18 Mar 2024 | 13,700 | 136,300 | - | - | Stock Option (Right to Buy) | ||
| Mr. Andrew S. Rappaport | Director | Other type of transaction at price $ 0.00 per share. | 05 Mar 2024 | 385,965 | 385,965 | - | 0 | Common Stock | |
| Mr. Andrew S. Rappaport | Director | Other type of transaction at price $ 0.00 per share. | 05 Mar 2024 | 481,014 | 0 | - | 0 | Common Stock | |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 29 Feb 2024 | 100 | 846,283 | - | 13 | 1,300 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 12.41 per share. | 29 Feb 2024 | 24,900 | 846,383 | - | 12.4 | 309,009 | Common Stock |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | 01 Feb 2024 | 304,500 | 304,500 | - | - | Stock Option (Right to Buy) | ||
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | 01 Feb 2024 | 195,000 | 195,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | 01 Feb 2024 | 195,000 | 195,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean P. Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | 01 Feb 2024 | 621,500 | 621,500 | - | - | Stock Option (Right to Buy) | ||
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 12.23 per share. | 31 Jan 2024 | 25,000 | 876,283 | - | 12.2 | 305,750 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 15.56 per share. | 31 Jan 2024 | 5,000 | 871,283 | - | 15.6 | 77,800 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.02 per share. | 25 Jan 2024 | 20,000 | 66,664 | - | 7.0 | 140,400 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | 25 Jan 2024 | 20,000 | 214,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | 12 Jan 2024 | 50,000 | 187,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.02 per share. | 12 Jan 2024 | 50,000 | 484,987 | - | 7.0 | 351,000 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 13.30 per share. | 29 Dec 2023 | 22,500 | 903,783 | - | 13.3 | 299,250 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 14.10 per share. | 29 Dec 2023 | 2,500 | 901,283 | - | 14.1 | 35,250 | Common Stock |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | 12 Dec 2023 | 10,000 | 237,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.02 per share. | 12 Dec 2023 | 10,000 | 434,987 | - | 7.0 | 70,200 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.02 per share. | 11 Dec 2023 | 2,900 | 46,664 | - | 7.0 | 20,358 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | 11 Dec 2023 | 2,900 | 234,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.02 per share. | 06 Dec 2023 | 13,100 | 43,764 | - | 7.0 | 91,962 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | 06 Dec 2023 | 13,100 | 236,900 | - | - | Stock Option (Right to Buy) | ||
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 12.57 per share. | 30 Nov 2023 | 25,000 | 926,283 | - | 12.6 | 314,250 | Common Stock |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Sale of securities on an exchange or to another person at price $ 15.27 per share. | 20 Nov 2023 | 700 | 434,132 | - | 15.3 | 10,689 | Common Stock |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2023 | 36,750 | 443,729 | - | 0 | Common Stock | |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Sale of securities on an exchange or to another person at price $ 14.83 per share. | 20 Nov 2023 | 8,897 | 434,832 | - | 14.8 | 131,943 | Common Stock |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Sale of securities on an exchange or to another person at price $ 13.89 per share. | 20 Nov 2023 | 9,145 | 424,987 | - | 13.9 | 127,024 | Common Stock |
| Dr. Sean P. Bohen, M.D. | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 14.84 per share. | 20 Nov 2023 | 26,691 | 175,459 | - | 14.8 | 396,094 | Common Stock |
| Dr. Sean P. Bohen, M.D. | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 13.90 per share. | 20 Nov 2023 | 27,932 | 144,925 | - | 13.9 | 388,255 | Common Stock |
| Dr. Sean P. Bohen, M.D. | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 15.29 per share. | 20 Nov 2023 | 2,602 | 172,857 | - | 15.3 | 39,785 | Common Stock |
| Dr. Sean P. Bohen, M.D. | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2023 | 110,250 | 202,150 | - | 0 | Common Stock | |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 13.90 per share. | 20 Nov 2023 | 3,989 | 951,283 | - | 13.9 | 55,447 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2023 | 15,750 | 959,464 | - | 0 | Common Stock | |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 14.86 per share. | 20 Nov 2023 | 4,192 | 955,272 | - | 14.9 | 62,293 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 15.32 per share. | 20 Nov 2023 | 200 | 580,752 | - | 15.3 | 3,064 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2023 | 26,250 | 587,728 | - | 0 | Common Stock | |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 14.87 per share. | 20 Nov 2023 | 6,776 | 580,952 | - | 14.9 | 100,759 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 13.89 per share. | 20 Nov 2023 | 6,653 | 574,099 | - | 13.9 | 92,410 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 13.89 per share. | 20 Nov 2023 | 7,095 | 30,664 | - | 13.9 | 98,550 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2023 | 28,000 | 45,220 | - | 0 | Common Stock | |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 14.83 per share. | 20 Nov 2023 | 7,261 | 37,959 | - | 14.8 | 107,681 | Common Stock |
| Dr. Naseem Zojwalla, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.33 per share. | 20 Nov 2023 | 200 | 37,759 | - | 15.3 | 3,066 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 17.61 per share. | 08 Nov 2023 | 200 | 561,270 | - | 17.6 | 3,522 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 15.36 per share. | 01 Nov 2023 | 3,332 | 562,011 | - | 15.4 | 51,180 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 15.02 per share. | 01 Nov 2023 | 6,668 | 565,343 | - | 15.0 | 100,153 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 17.51 per share. | 01 Nov 2023 | 541 | 561,470 | - | 17.5 | 9,473 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 12.05 per share. | 31 Oct 2023 | 25,000 | 948,714 | - | 12.1 | 301,250 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 15.64 per share. | 31 Oct 2023 | 5,000 | 943,714 | - | 15.6 | 78,200 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 12.41 per share. | 29 Sep 2023 | 25,000 | 973,714 | - | 12.4 | 310,250 | Common Stock |
| Dr. David C. Myles, PhD | CH. DISCOV. & NON-CLIN DEV OFF | Sale of securities on an exchange or to another person at price $ 12.67 per share. | 19 Sep 2023 | 20,000 | 572,011 | - | 12.7 | 253,400 | Common Stock |
| Dr. Graham Walmsley, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 13.08 per share. | 12 Sep 2023 | 50,000 | 1,800,000 | - | 13.1 | 654,250 | Common Stock |
| Dr. Graham Walmsley, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 14.95 per share. | 12 Sep 2023 | 50,000 | 1,750,000 | - | 14.9 | 747,480 | Common Stock |
| Dr. Graham Walmsley, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 9.84 per share. | 12 Sep 2023 | 508,130 | 1,668,130 | - | 9.8 | 4,999,999 | Common Stock |
| Dr. Graham Walmsley, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 14.73 per share. | 12 Sep 2023 | 31,870 | 1,700,000 | - | 14.7 | 469,550 | Common Stock |
| Dr. Graham Walmsley, M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 14.85 per share. | 12 Sep 2023 | 475,000 | 708,114 | - | 14.9 | 7,053,750 | Common Stock |
| Dr. Graham Walmsley, M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 14.85 per share. | 12 Sep 2023 | 700,000 | 700,761 | - | 14.9 | 10,395,000 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 9.36 per share. | 31 Aug 2023 | 15,000 | 1,008,714 | - | 9.4 | 140,400 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 11.62 per share. | 31 Aug 2023 | 10,000 | 998,714 | - | 11.6 | 116,200 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 10.14 per share. | 16 Aug 2023 | 15,000 | 1,023,714 | - | 10.1 | 152,100 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 10.14 per share. | 16 Aug 2023 | 15,000 | 1,023,714 | - | 10.1 | 152,100 | Common Stock |
| Mr. Andrew S. Rappaport | Director | 16 Jun 2023 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Ms. Cynthia M. Butitta | Director | 16 Jun 2023 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Mr. Ian T. Clark | Director | 16 Jun 2023 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Dr. Sandra J. Horning, M.D. | Director | 16 Jun 2023 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Dr. Graham Walmsley, M.D.,PhD | Director | 16 Jun 2023 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Ms. Yi Larson | Director | 16 Jun 2023 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Dr. Gorjan Hrustanovic, PhD | Director | 16 Jun 2023 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 6.30 per share. | 08 Jun 2023 | 10,000 | 1,038,714 | - | 6.3 | 63,000 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 6.30 per share. | 05 Jun 2023 | 5,000 | 1,048,714 | - | 6.3 | 31,475 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director | Sale of securities on an exchange or to another person at price $ 6.04 per share. | 05 Jun 2023 | 5,000 | 1,053,714 | - | 6.0 | 30,225 | Common Stock |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Apr 2023 | 10,000 | 396,197 | - | - | Common Stock | |
| Mr. John B. Moriarty, J.D. | EVP, Ch. Legal Officer & Sec. | 01 Feb 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Shane Kovacs | Ch. Operating & Financial Off. | 01 Feb 2023 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean P. Bohen, M.D. | Director, President and CEO | 01 Feb 2023 | 550,000 | 550,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Cyrus L. Harmon, PhD | Director, Chief Research Officer | 01 Feb 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. David C. Myles, PhD | Chief Development Officer | 01 Feb 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | Chief Business Officer | 01 Feb 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Naseem Zojwalla, M.D. | Chief Medical Officer | 01 Feb 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2022 | 20,000 | 74,279 | - | - | Common Stock | |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 21 Sep 2022 | 20,000 | 74,279 | - | - | - | |
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 02 Sep 2022 | 20,000 | 381,197 | - | - | Common Stock | |
| Mr. Andrew S. Rappaport | Director | 17 Jun 2022 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Ms. Cynthia M. Butitta | Director | 17 Jun 2022 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Mr. Ian T. Clark | Director | 17 Jun 2022 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Dr. Sandra J. Horning, M.D. | Director | 17 Jun 2022 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Dr. Graham Walmsley, M.D.,PhD | Director | 17 Jun 2022 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Ms. Yi Larson | Director | 17 Jun 2022 | 21,520 | 21,520 | - | - | Stock Option (Right to Buy) | ||
| Dr. Gorjan Hrustanovic, PhD | Director | 17 Jun 2022 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 10 Mar 2022 | 5,253 | 2,458 | - | 4.8 | 24,952 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 10 Mar 2022 | 5,253 | 141,785 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 10 Mar 2022 | 5,253 | 7,711 | - | 2.1 | 10,842 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 10 Feb 2022 | 5,251 | 147,038 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 10 Feb 2022 | 5,251 | 7,709 | - | 2.1 | 10,838 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 10 Feb 2022 | 5,251 | 2,458 | - | - | Common Stock | |
| Mr. John B. Moriarty, J.D. | EVP, CH. LEGAL OFFICER & SEC. | 01 Feb 2022 | 166,250 | 166,250 | - | - | Stock Option (Right to Buy) | ||
| Mr. Shane Kovacs | CH. OPERATING & FINANCIAL OFF. | 01 Feb 2022 | 247,000 | 247,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | 01 Feb 2022 | 812,250 | 812,250 | - | - | Stock Option (Right to Buy) | ||
| Dr. Cyrus L. Harmon, PhD | Director, CHIEF TECHNOLOGY OFFICER | 01 Feb 2022 | 104,500 | 104,500 | - | - | Stock Option (Right to Buy) | ||
| Dr. Peter J. Kushner, PhD | CHIEF SCIENTIFIC OFFICER | 01 Feb 2022 | 61,750 | 61,750 | - | - | Stock Option (Right to Buy) | ||
| Dr. David C. Myles, PhD | CHIEF DEVELOPMENT OFFICER | 01 Feb 2022 | 118,750 | 118,750 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 01 Feb 2022 | 133,000 | 133,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Naseem Zojwalla | CHIEF MEDICAL OFFICER | 01 Feb 2022 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 6.85 per share. | 10 Jan 2022 | 5,251 | 2,458 | - | 6.8 | 35,969 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 10 Jan 2022 | 5,251 | 152,289 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 10 Jan 2022 | 5,251 | 7,709 | - | 2.1 | 10,838 | Common Stock |
| Dr. David C. Myles, PhD | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 10.30 per share. | 10 Dec 2021 | 10,000 | 582,901 | - | 10.3 | 103,000 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 10 Dec 2021 | 5,251 | 7,709 | - | 2.1 | 10,838 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 10 Dec 2021 | 5,251 | 157,540 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 10.39 per share. | 10 Dec 2021 | 5,251 | 2,458 | - | 10.4 | 54,558 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director, CHIEF TECHNOLOGY OFFICER | Sale of securities on an exchange or to another person at price $ 24.76 per share. | 29 Nov 2021 | 400 | 1,051,146 | - | 24.8 | 9,904 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.00 per share. | 10 Nov 2021 | 22,417 | 29,458 | - | 19 | 425,923 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 10 Nov 2021 | 22,417 | 67,253 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 10 Nov 2021 | 5,251 | 162,791 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 26.88 per share. | 10 Nov 2021 | 27,668 | 1,790 | - | 26.9 | 743,716 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 10 Nov 2021 | 5,251 | 7,041 | - | 2.1 | 10,838 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director, CHIEF TECHNOLOGY OFFICER | Sale of securities on an exchange or to another person at price $ 28.20 per share. | 19 Oct 2021 | 4,555 | 1,051,546 | - | 28.2 | 128,451 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director, CHIEF TECHNOLOGY OFFICER | Sale of securities on an exchange or to another person at price $ 27.85 per share. | 19 Oct 2021 | 7,445 | 1,056,101 | - | 27.8 | 207,343 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 30.42 per share. | 14 Oct 2021 | 4,649 | 52,865 | - | 30.4 | 141,423 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | 14 Oct 2021 | 5,000 | 966,316 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 31.17 per share. | 14 Oct 2021 | 351 | 52,514 | - | 31.2 | 10,941 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.82 per share. | 14 Oct 2021 | 5,000 | 57,514 | - | 4.8 | 24,120 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 27.47 per share. | 11 Oct 2021 | 2,105 | 4,936 | - | 27.5 | 57,824 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 11 Oct 2021 | 5,251 | 168,042 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 28.19 per share. | 11 Oct 2021 | 3,146 | 1,790 | - | 28.2 | 88,686 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 11 Oct 2021 | 5,251 | 7,041 | - | 2.1 | 10,838 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 30.07 per share. | 27 Sep 2021 | 1,085 | 52,514 | - | 30.1 | 32,626 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | 27 Sep 2021 | 1,085 | 971,316 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.82 per share. | 27 Sep 2021 | 1,085 | 53,599 | - | 4.8 | 5,234 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director, CHIEF TECHNOLOGY OFFICER | Sale of securities on an exchange or to another person at price $ 26.30 per share. | 20 Sep 2021 | 12,000 | 1,063,546 | - | 26.3 | 315,600 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 29.38 per share. | 10 Sep 2021 | 5,251 | 1,790 | - | 29.4 | 154,274 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 10 Sep 2021 | 5,251 | 173,293 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 10 Sep 2021 | 5,251 | 7,041 | - | 2.1 | 10,838 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.82 per share. | 07 Sep 2021 | 413 | 54,687 | - | 4.8 | 1,992 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 30.08 per share. | 07 Sep 2021 | 413 | 54,274 | - | 30.1 | 12,423 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.82 per share. | 07 Sep 2021 | 2,631 | 56,905 | - | 4.8 | 12,692 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 07 Sep 2021 | 2,631 | 52,514 | - | 30 | 78,930 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | 07 Sep 2021 | 413 | 975,032 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | 07 Sep 2021 | 2,631 | 972,401 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.82 per share. | 01 Sep 2021 | 871 | 55,145 | - | 4.8 | 4,202 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 01 Sep 2021 | 871 | 54,274 | - | 30.1 | 26,174 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, PRESIDENT AND CEO | 01 Sep 2021 | 871 | 975,445 | - | - | Stock Option (Right to Buy) | ||
| Dr. Cyrus L. Harmon, PhD | Director, CHIEF TECHNOLOGY OFFICER | Sale of securities on an exchange or to another person at price $ 24.97 per share. | 19 Aug 2021 | 12,000 | 1,075,546 | - | 25.0 | 299,640 | - |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 25.70 per share. | 10 Aug 2021 | 5,191 | 1,850 | - | 25.7 | 133,409 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 10 Aug 2021 | 5,251 | 178,544 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 10 Aug 2021 | 5,251 | 7,041 | - | 2.1 | 10,838 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 26.17 per share. | 10 Aug 2021 | 60 | 1,790 | - | 26.2 | 1,570 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director, CHIEF TECHNOLOGY OFFICER | Sale of securities on an exchange or to another person at price $ 25.63 per share. | 20 Jul 2021 | 4,123 | 1,087,546 | - | 25.6 | 105,672 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director, CHIEF TECHNOLOGY OFFICER | Sale of securities on an exchange or to another person at price $ 24.83 per share. | 20 Jul 2021 | 7,877 | 1,091,669 | - | 24.8 | 195,586 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 26.33 per share. | 12 Jul 2021 | 3,859 | 3,182 | - | 26.3 | 101,607 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 12 Jul 2021 | 5,251 | 183,795 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 12 Jul 2021 | 1,392 | 1,790 | - | 27 | 37,584 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 12 Jul 2021 | 5,251 | 7,041 | - | 2.1 | 10,838 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director, CHIEF TECHNOLOGY OFFICER | Sale of securities on an exchange or to another person at price $ 25.59 per share. | 18 Jun 2021 | 1,990 | 1,100,146 | - | 25.6 | 50,924 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director, CHIEF TECHNOLOGY OFFICER | Sale of securities on an exchange or to another person at price $ 26.30 per share. | 18 Jun 2021 | 600 | 1,099,546 | - | 26.3 | 15,780 | Common Stock |
| Dr. Cyrus L. Harmon, PhD | Director, CHIEF TECHNOLOGY OFFICER | Sale of securities on an exchange or to another person at price $ 24.54 per share. | 18 Jun 2021 | 9,410 | 1,102,136 | - | 24.5 | 230,921 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 10 Jun 2021 | 5,251 | 7,041 | - | 2.1 | 10,838 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 10 Jun 2021 | 5,251 | 189,046 | - | - | Stock Option (right to buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 29.97 per share. | 10 Jun 2021 | 2,787 | 1,790 | - | 30.0 | 83,526 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 29.60 per share. | 10 Jun 2021 | 2,164 | 4,577 | - | 29.6 | 64,054 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 28.30 per share. | 10 Jun 2021 | 300 | 6,741 | - | 28.3 | 8,490 | Common Stock |
| Mr. Andrew S. Rappaport | Director | 09 Jun 2021 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Ms. Cynthia M. Butitta | Director | 09 Jun 2021 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Mr. Ian T. Clark | Director | 09 Jun 2021 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Dr. Sandra J. Horning, M.D. | Director | 09 Jun 2021 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Dr. Graham Walmsley, M.D.,PhD | Director | 09 Jun 2021 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Ms. Yi Larson | Director | 09 Jun 2021 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Dr. Gorjan Hrustanovic, PhD | Director | 09 Jun 2021 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 24.03 per share. | 18 May 2021 | 49,142 | 10,411 | - | 24.0 | 1,180,882 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 18 May 2021 | 57,763 | 59,553 | - | 2.1 | 119,223 | Common Stock |
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | 18 May 2021 | 57,763 | 194,297 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 24.81 per share. | 18 May 2021 | 8,621 | 1,790 | - | 24.8 | 213,887 | Common Stock |
| Ms. Yi Larson | Director | 05 Apr 2021 | 21,520 | 21,520 | - | - | Stock Option (Right to Buy) | ||
| Ms. Yi Larson | Director | 05 Apr 2021 | 3,773 | 3,773 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean Bohen, M.D.,PhD | Director, President and CEO | 15 Mar 2021 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | Chief Business Officer | 15 Mar 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Andrew S. Rappaport | Director | 23 Nov 2020 | 318,723 | 351,181 | - | - | Common Stock | ||
| Mr. Andrew S. Rappaport | Director | 23 Nov 2020 | 129,833 | 0 | - | - | Series A-1 Convertible Preferred Stock | ||
| Mr. Andrew S. Rappaport | Director | 23 Nov 2020 | 318,723 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Mr. Andrew S. Rappaport | Director | 23 Nov 2020 | 129,833 | 481,014 | - | - | Common Stock | ||
| Dr. Frank McCormick, D.Sc.,F.R.S.,PhD | Director | 23 Nov 2020 | 66,326 | 84,260 | - | - | Common Stock | ||
| Dr. Frank McCormick, D.Sc.,F.R.S.,PhD | Director | 23 Nov 2020 | 66,326 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Dr. Frank McCormick, D.Sc.,F.R.S.,PhD | Director | 23 Nov 2020 | 152,891 | 0 | - | - | Series A-1 Convertible Preferred Stock | ||
| Dr. Frank McCormick, D.Sc.,F.R.S.,PhD | Director | 23 Nov 2020 | 152,891 | 191,113 | - | - | Common Stock | ||
| Dr. Graham Walmsley, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 23 Nov 2020 | 1,160,000 | 1,160,000 | - | 19 | 22,040,000 | Common Stock |
| Dr. Graham Walmsley, M.D.,PhD | Director | 23 Nov 2020 | 1,183,114 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Dr. Graham Walmsley, M.D.,PhD | Director | 23 Nov 2020 | 1,400,761 | 1,400,761 | - | - | Common Stock | ||
| Dr. Graham Walmsley, M.D.,PhD | Director | 23 Nov 2020 | 1,183,114 | 1,183,114 | - | - | Common Stock | ||
| Dr. Graham Walmsley, M.D.,PhD | Director | 23 Nov 2020 | 1,400,761 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Dr. Cyrus L. Harmon, PhD | Director, Chief Technology Officer | 23 Nov 2020 | 122,028 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Dr. Cyrus L. Harmon, PhD | Director, Chief Technology Officer | 23 Nov 2020 | 71,374 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Dr. Cyrus L. Harmon, PhD | Director, Chief Technology Officer | 23 Nov 2020 | 71,374 | 1,111,546 | - | - | Common Stock | ||
| Dr. Cyrus L. Harmon, PhD | Director, Chief Technology Officer | 23 Nov 2020 | 122,028 | 122,028 | - | - | Common Stock | ||
| Dr. Peter J. Kushner, PhD | Chief Scientific Officer | 23 Nov 2020 | 130,159 | 1,431,672 | - | - | Common Stock | ||
| Dr. Peter J. Kushner, PhD | Chief Scientific Officer | 23 Nov 2020 | 228,761 | 1,301,513 | - | - | Common Stock | ||
| Dr. Peter J. Kushner, PhD | Chief Scientific Officer | 23 Nov 2020 | 130,159 | 0 | - | - | Series A-1 Convertible Preferred Stock | ||
| Dr. Peter J. Kushner, PhD | Chief Scientific Officer | 23 Nov 2020 | 228,761 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Dr. David C. Myles, PhD | Chief Development Officer | 23 Nov 2020 | 12,831 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Dr. David C. Myles, PhD | Chief Development Officer | 23 Nov 2020 | 154,846 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Dr. David C. Myles, PhD | Chief Development Officer | 23 Nov 2020 | 154,846 | 154,846 | - | - | Common Stock | ||
| Dr. David C. Myles, PhD | Chief Development Officer | 23 Nov 2020 | 12,831 | 12,831 | - | - | Common Stock | ||
| Dr. Sandra J. Horning, M.D. | Director | 18 Nov 2020 | 86,083 | 86,083 | - | - | Stock Option (Right to Buy) | ||
| Dr. Gorjan Hrustanovic, PhD | Director | 18 Nov 2020 | 21,520 | 21,520 | - | - | Stock Option (Right to Buy) | ||
| Dr. Gorjan Hrustanovic, PhD | Director | 18 Nov 2020 | 21,520 | 21,520 | - | - | Stock Option (Right to Buy) | ||
| Dr. Gorjan Hrustanovic, PhD | Director | 18 Nov 2020 | 21,520 | 21,520 | - | - | Stock Option (Right to Buy) | ||
| Mr. John Moriarty, J.D.,Jr | EVP, Ch. Legal Officer & Sec. | 19 Sep 2020 | 252,060 | 252,060 | - | - | Stock Option (Right to Buy) | ||
| Mr. John Moriarty, J.D.,Jr | EVP, Ch. Legal Officer & Sec. | 19 Sep 2020 | 161,406 | 161,406 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean Bohen, M.D.,PhD | Director, President and CEO | 19 Sep 2020 | 538,020 | 538,020 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean Bohen, M.D.,PhD | Director, President and CEO | 19 Sep 2020 | 1,027,965 | 1,027,965 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean Bohen, M.D.,PhD | Director, President and CEO | 19 Sep 2020 | 51,649 | 976,316 | - | - | Stock Option (Right to Buy) | ||
| Dr. Sean Bohen, M.D.,PhD | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.82 per share. | 19 Sep 2020 | 51,649 | 51,649 | - | 4.8 | 249,155 | Common Stock |
| Dr. Sean Bohen, M.D.,PhD | Director, President and CEO | 19 Sep 2020 | 82,931 | 82,931 | - | - | Stock Option (Right to Buy) | ||
| Mr. Andrew S. Rappaport | Director | 18 Sep 2020 | 21,520 | 21,520 | - | - | Stock Option (Right to Buy) | ||
| Mr. Andrew S. Rappaport | Director | 18 Sep 2020 | 56,964 | 56,964 | - | - | Stock Option (Right to Buy) | ||
| Dr. Frank McCormick, D.Sc.,F.R.S.,PhD | Director | 18 Sep 2020 | 21,520 | 21,520 | - | - | Stock Option (Right to Buy) | ||
| Dr. Frank McCormick, D.Sc.,F.R.S.,PhD | Director | 18 Sep 2020 | 56,964 | 56,964 | - | - | Stock Option (Right to Buy) | ||
| Ms. Cynthia M. Butitta | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.41 per share. | 12 Aug 2020 | 83,876 | 83,876 | - | 4.4 | 369,558 | Common Stock |
| Ms. Cynthia M. Butitta | Director | 12 Aug 2020 | 21,520 | 21,520 | - | - | Stock Option (Right to Buy) | ||
| Ms. Cynthia M. Butitta | Director | 12 Aug 2020 | 83,876 | 0 | - | - | Stock Option (Right to Buy) | ||
| Ms. Cynthia M. Butitta | Director | 12 Aug 2020 | 83,876 | 83,876 | - | - | Stock Option (Right to Buy) | ||
| Mr. Ian T. Clark | Director | 12 Aug 2020 | 209,690 | 209,690 | - | - | Stock Option (Right to Buy) | ||
| Mr. Ian T. Clark | Director | 12 Aug 2020 | 21,520 | 21,520 | - | - | Stock Option (Right to Buy) | ||
| Mr. Shane Kovacs | Ch. Operating & Financial Off. | 15 Jun 2020 | 107,604 | 107,604 | - | - | Stock Option (Right to Buy) | ||
| Mr. Shane Kovacs | Ch. Operating & Financial Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2020 | 358,680 | 358,680 | - | 0 | Common Stock | |
| Dr. Cyrus L. Harmon, PhD | Director, Chief Technology Officer | 15 Jun 2020 | 1,076 | 1,076 | - | - | Stock Option (Right to Buy) | ||
| Dr. Peter J. Kushner, PhD | Chief Scientific Officer | 15 Jun 2020 | 179,340 | 179,340 | - | - | Stock Option (Right to Buy) | ||
| Dr. Peter J. Kushner, PhD | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2020 | 143,472 | 1,072,752 | - | 0 | Common Stock | |
| Dr. David C. Myles, PhD | Chief Development Officer | 15 Jun 2020 | 179,340 | 179,340 | - | - | Stock Option (Right to Buy) | ||
| Dr. David C. Myles, PhD | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2020 | 143,472 | 591,821 | - | 0 | Common Stock | |
| Mr. Kinney Horn | Chief Business Officer | 10 Jun 2020 | 252,060 | 252,060 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kinney Horn | Chief Business Officer | 10 Jun 2020 | 89,670 | 89,670 | - | - | Stock Option (Right to Buy) | ||
| Dr. Graham Walmsley, M.D.,PhD | Director | 01 Jun 2020 | 339,578 | 1,400,761 | - | - | Series B Convertible Preferred Stock |